A concise overview of the real-world data for Vyxeos Liposomal from the French and Italian cohorts in a handy format you can access offline.
This site is intended for United Kingdom/Ireland healthcare professionals
Acute Myeloid Leukaemia Resources
Welcome to the resource centre.
You can filter the resources by topic and category to find those that best match your needs.
Selecting a resource will open the material in a new tab.
Filter
- View data
-
Vyxeos Liposomal in AML-MRC and t-AML patients: See how Vyxeos Liposomal compares in French and Italian cohortsTopics
Real-world Data Safety Vyxeos Liposomal Data
UK-VYX-2100231 | October 2021
-
12 mins
Lancet J, et al. Lancet Haematol. 2021: The 5-year analysis of Study 301In this final analysis of the Phase III pivotal trial for Vyxeos Liposomal, the authors present the OS outcomes for the overall ITT population, as well as a breakdown of the results by patient age, cytogentic profile, prior HMA exposure, consolidation therapy, and more.
Topics
Cytogenetics Safety Vyxeos Liposomal Data
UK-VYX-2100177 | September 2021
-
10 mins
The Impact of Vyxeos Liposomal on patients with t-AML and AML-MRC – The French ExperienceExplore the outcomes of 103 patients treated with Vyxeos Liposomal in this French multicentric cohort. The study presents multiple efficacy endpoints, including MRD-negativity prior to HSCT, and contributes to the current understanding of the Vyxeos Liposomal tolerability profile.
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2100176 | September 2021
-
9 mins
Guolo F, et al. Blood Cancer J. 2020: Treatment with Vyxeos Liposomal in a compassionate use programDiscover the full outcomes of this multicentre cohort in Italy, where 71 patients were treated with Vyxeos Liposomal showing a 12-month OS of 68.6% and a manageable adverse events profile.1
- Guolo F, et al. Blood Cancer J 2020;10.1038/s41408-020-00361-8
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2100175 | September 2021
-
3 mins
Vyxeos Liposomal: Licence and Indication cardAll the details you need on the indication and reimbursement status of Vyxeos Liposomal are available at a glance in this card.
Topics
Practicalities
UK-VYX-2100126 | May 2021
-
1 min
The NCRI Guidelines on High-risk AML Patients: A SummaryWatch as Dr Erin Hurst, Consultant Haematologist at the Newcastle upon Tyne Hospitals NHS Foundation Trust, gives an overview of the AML working group guidelines on treating adverse risk AML during the COVID pandemic.
Topics
AML Landscape
UK-VYX-2100095 | August 2021
-
1 min
The American Society of Hematology (ASH) Guidelines: A Summary by Dr Priyanka MehtaA brief summary from Dr Priyanka Mehta of the latest American Society of Hematology (ASH) recommendations for the treatment of older patients with AML.
Topics
Practicalities Safety
UK-VYX-2100030 | March 2021
-
53 mins
Strategies for Maximising Survival: Advances in High-Risk* Acute Myeloid Leukaemia (AML)This Continuing Professional Development (CPD) accredited webinar gives an overview of the current AML landscape and provides insights from evidence-based practice on managing patients with AML.
Topics
Ambulatory care AML Landscape Cytogenetics Vyxeos Liposomal Data
UK-VYX-2100054 | May 2021
-
90 mins
Optimising Care For Patients With High-Risk AML – BSH Symposia 2021Dr Amit Patel chairs the panel alongside Prof. Thomas Cluzeau and Dr Sree Munisamy. In the Symposium, Dr Patel will define high-risk AML, while providing a background to the breakthrough trials of Vyxeos Liposomal. Prof. Cluzeau presents the case study of a 69-year-old French woman, in addition to describing the real-world evidence of Vyxeos Liposomal in French and Italian centres. Finally, Dr Munisamy will review the Q-TWiST (QoL) study in the context of the case study of a 69-year-old British woman who contracted COVID-19 during the course of her treatment.
Topics
Cytogenetics Quality of Life Real-world Data Safety Vyxeos Liposomal Data
UK-VYX-2100137 | July 2021
-
14 mins
71-Year-Old Male Patient With Therapy-Related AMLDr Deepak Mannari explores the case study of a patient with treatment related AML following prostate cancer therapy; explaining the management of the condition with Vyxeos Liposomal to induce morphological and cytogenetic remission.
Topics
AML Landscape Safety Vyxeos Liposomal Data
UK-VYX-2100018 | May 2021
-
18 mins
69-Year-Old Female Patient Who Developed Corona Virus Disease 2019 (COVID-19) During TreatmentDr Sree Munisami shares how he and his team navigated the challenges of treating a high-risk* patient who caught COVID-19 during the course of her acute myeloid leukaemia (AML) therapy.
UK-VYX-2100015 | April 2021
-
13 mins
67-Year-Old Male Patient With Acute Myeloid Leukaemia With Myelodysplasia-Related Changes (AML-MRC) and a Complex KaryotypeDr Satarupa Choudhuri presents a case study of a high-risk* AML patient who was treated during the COVID pandemic.
Topics
AML Landscape Safety Vyxeos Liposomal Data
UK-VYX-2100014 | March 2021
-
3 mins
Selecting the Right Treatment for Your Patient: Balancing the Needs for Cytogenetic Testing With the Urgency of Treatment InitiationDr Erin Hurst and Dr Priyanka Mehta discuss striking the right balance between using cytogenetic testing to inform treatment decisions in patients with acute myeloid leukaemia and initiating treatment as soon as possible, and how to utilise the time between cytogenetic test and results effectively.
Topics
Cytogenetics
UK-VYX-2100032 | March 2021
-
3 mins
A New Era in Acute Myeloid Leukaemia (AML): The Importance of Cytogenetic TestingWatch as Prof. Nigel Russell talks about the importance of cytogenetic testing in treatment decision-making for patients with AML.
Topics
AML Landscape Cytogenetics
UK-VYX-2000173 | March 2021
-
10 mins
Integrating Cytogenetics in Acute Myeloid Leukaemia (AML) Decision-Making: A Case StudyDr Priyanka Mehta, Consultant Haematologist, and Dr Rachel Protheroe, Haematologist and Transplant Consultant, both from the University Hospitals Bristol discuss their approach in treating patients with AML and how cytogenetic testing has transformed this approach. While Consultant Clinical Scientist of the Bristol Genetics Laboratory, Dr Chris Wragg, gives an overview of the cytogenetic testing process in his lab and the changes he has implemented so results can be made available in a timely manner.
Topics
Cytogenetics
UK-VYX-2000174 | March 2021
-
3 mins
Administering Vyxeos Liposomal in an Ambulatory Setting: A Real-World ExperienceDr Priyanka Mehta explains the approach her team took to start treating patients in an ambulatory setting and how she assesses which patients with acute myeloid leukaemia would be suitable for outpatient care.
Topics
Ambulatory care Practicalities
UK-VYX-2100031 | March 2021
-
6 mins
Establishing a Successful Ambulatory Service to Benefit Patients and Your TrustDr Rachel Protheroe, Haematology and Stem Cell Consultant from University Hospitals Bristol and Weston NHS Foundation Trust, shares her experience of setting up an ambulatory service and treating patients with Vyxeos Liposomal in an outpatient setting.
Topics
Ambulatory care Practicalities
UK-VYX-2100029 | March 2021
-
4 mins
5-Year Data for Vyxeos Liposomal: Perspectives From the United Kingdom (UK)Watch as physicians from leading UK haematology centres share their thoughts on the 5-year results of Vyxeos Liposomal in Study 301, presented at the European Hematology Association (EHA) Virtual Congress 2020.1
- Lancet JE, et al. E-poster EP556. EHA25 Virtual Congress 2020
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2000171 | March 2021
-
12 mins
Laying the Foundations for Long-Term Remission in High-Risk* Acute Myeloid Leukaemia (AML)Dr Donal McLornan presents a case study in the context of the 5-year data for Vyxeos Liposomal.1
- Lancet JE, et al. E-poster EP556. EHA25 Virtual Congress 2020
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2100027 | March 2021
-
15 mins
A 64-Year-Old Male Patient Who Proceeded To TransplantDr Deepak Mannari, Consultant Haematologist at Musgrove Park Hospital Somerset, shares the case study of an AML patient with MDS who received two courses of Vyxeos Liposomal and a sibling allograft HSCT to induce complete remission.
Topics
AML Landscape Safety Vyxeos Liposomal Data
UK-VYX-2100023 | May 2021
-
8 mins
Vyxeos Liposomal: Practical InformationThis leaflet contains useful information on the indication and reimbursement status of Vyxeos Liposomal, as well as detailed instructions on how to prepare, store and administer the treatment.
Topics
Practicalities
UK-VYX-2100129 l June 2021
-
5 mins
Preparation and HandlingLearn how to prepare and store the Vyxeos Liposomal infusion with this video.
Topics
Practicalities
UK-VYX-2100028 | March 2021
-
10 mins
Vyxeos Liposomal: Patient InformationA simple guide to help patients understand everything they need to know about their treatment with Vyxeos Liposomal.
Topics
Practicalities Safety Vyxeos Liposomal Data
UK-VYX-2100144 l June 2021
-
4 mins
Mode of Action (MoA) and Phase III DataLearn about the MoA of Vyxeos Liposomal, as well as the Phase III data in high-risk* acute myeloid leukaemia (AML) patients.
Topics
Safety Vyxeos Liposomal Data
UK-VYX-2000172 | March 2021
